Hematological responses
| Patient no.* . | FAB . | BM cellularity . | PRBC dependent . | Responses . | Response type . | Response duration, d† . | Comment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Before . | After . | Before . | After . | Reduction in PRBC, % . | Increase in Hb . | Platelets . | ANC . | ||||
| 937 | RA | RA | 20 | 30 | Y | N | 100 | Yes | No | No | HI-E major, 100% PRBC Tx reduction at wk 16; minor Hb response at wk 16 | 200 | Died of lymphoma |
| 1011 | RA | RARS | 99 | 70 | Y | N | 100 | Yes | No | No | HI-E major (PRBC), Tx independent at wk 16; major (Hb) | 422+ | Continues in remission |
| 277 | RA | RA | 90 | N/A | Y | N | 100 | No | No | No | HI-E major, 100% PRBC Tx reduction | 454+ | Continues in remission |
| 963 | RA | RARS | 80 | 90 | Y | N | 100 | No | No | No | HI-E major | 227 | Stopped responding |
| 400 | RARS | RARS | 70 | 70 | Y | Y | 50 | No | No | No | HI-E minor, 50% PRBC Tx reduction | 306 | Stopped after 1 year owing to side effects |
| 460 | RARS | RARS | 50 | 50 | N | N | Yes | No | No | HI-E major (Hb) | 620+ | Continues in remission | |
| 1016 | RA | RA | 30 | 30 | Y | N | 100 | Yes | No | No | HI-E major | 527+ | Continues in remission |
| 340 | RARS | RA | 80 | 90 | Y | Y | 50 | No | No | No | HI-E minor, at 16 wks and post-50% reduction in PRBC Tx | 168 | Stopped responding |
| 333 | RARS | N/A | 50 | N/A | Y | Y | 50 | No | No | No | 50% PRBC reduction from wk 20 to wk 24 & 28 | 239 | Stopped owing to side effects |
| 585 | RARS | RA | 80 | 80 | Y | Y | No | No | Yes | No | H1-P minor | 90 | Stopped owing to side effects |
| 1023 | RAEB | RAEB | 60 | 70 | Y | N | 100 | No | No | No | HI-E major (PRBC), Tx independent at wk 16 | 177 | Stopped responding |
| 1007 | RA | RA | 20 | 30 | Y | Y | 50 | No | No | No | HI-E minor, 50% PRBC Tx reduction at wk 20, sustained for 8 wks | 365 | Stopped owing to side effects |
| 1010 | RAEB | RAEB | 40 | 10 | Y | N | 100 | Yes | No | No | HI-E major (PRBC) major (Hb) | 381 | Stopped responding |
| 988 | RA | RA | 80 | 70 | Y | N | 100 | No | Yes | No | HI-E major, 100% PRBC Tx reduction at wk 16, minor Plt response at wk 16 (not wk 12 owing to plt Tx) | 359 | Stopped responding |
| 551 | RA | RA | 30 | N/A | Y | N | 100 | No | No | No | HI-E major, Tx dependent until wk 20, then independent through wk 28 | 188 | Stopped responding |
| 274 | RA | RA | 10 | 30 | Y | N | 100 | No | No | No | HI-E major, patient received 2 U PRBC day 1 of treatment, then was Tx independent until wk 28 with 2 U, then independent again | 365 | Stopped after 1 year owing to side effects |
| Patient no.* . | FAB . | BM cellularity . | PRBC dependent . | Responses . | Response type . | Response duration, d† . | Comment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Before . | After . | Before . | After . | Reduction in PRBC, % . | Increase in Hb . | Platelets . | ANC . | ||||
| 937 | RA | RA | 20 | 30 | Y | N | 100 | Yes | No | No | HI-E major, 100% PRBC Tx reduction at wk 16; minor Hb response at wk 16 | 200 | Died of lymphoma |
| 1011 | RA | RARS | 99 | 70 | Y | N | 100 | Yes | No | No | HI-E major (PRBC), Tx independent at wk 16; major (Hb) | 422+ | Continues in remission |
| 277 | RA | RA | 90 | N/A | Y | N | 100 | No | No | No | HI-E major, 100% PRBC Tx reduction | 454+ | Continues in remission |
| 963 | RA | RARS | 80 | 90 | Y | N | 100 | No | No | No | HI-E major | 227 | Stopped responding |
| 400 | RARS | RARS | 70 | 70 | Y | Y | 50 | No | No | No | HI-E minor, 50% PRBC Tx reduction | 306 | Stopped after 1 year owing to side effects |
| 460 | RARS | RARS | 50 | 50 | N | N | Yes | No | No | HI-E major (Hb) | 620+ | Continues in remission | |
| 1016 | RA | RA | 30 | 30 | Y | N | 100 | Yes | No | No | HI-E major | 527+ | Continues in remission |
| 340 | RARS | RA | 80 | 90 | Y | Y | 50 | No | No | No | HI-E minor, at 16 wks and post-50% reduction in PRBC Tx | 168 | Stopped responding |
| 333 | RARS | N/A | 50 | N/A | Y | Y | 50 | No | No | No | 50% PRBC reduction from wk 20 to wk 24 & 28 | 239 | Stopped owing to side effects |
| 585 | RARS | RA | 80 | 80 | Y | Y | No | No | Yes | No | H1-P minor | 90 | Stopped owing to side effects |
| 1023 | RAEB | RAEB | 60 | 70 | Y | N | 100 | No | No | No | HI-E major (PRBC), Tx independent at wk 16 | 177 | Stopped responding |
| 1007 | RA | RA | 20 | 30 | Y | Y | 50 | No | No | No | HI-E minor, 50% PRBC Tx reduction at wk 20, sustained for 8 wks | 365 | Stopped owing to side effects |
| 1010 | RAEB | RAEB | 40 | 10 | Y | N | 100 | Yes | No | No | HI-E major (PRBC) major (Hb) | 381 | Stopped responding |
| 988 | RA | RA | 80 | 70 | Y | N | 100 | No | Yes | No | HI-E major, 100% PRBC Tx reduction at wk 16, minor Plt response at wk 16 (not wk 12 owing to plt Tx) | 359 | Stopped responding |
| 551 | RA | RA | 30 | N/A | Y | N | 100 | No | No | No | HI-E major, Tx dependent until wk 20, then independent through wk 28 | 188 | Stopped responding |
| 274 | RA | RA | 10 | 30 | Y | N | 100 | No | No | No | HI-E major, patient received 2 U PRBC day 1 of treatment, then was Tx independent until wk 28 with 2 U, then independent again | 365 | Stopped after 1 year owing to side effects |
BM indicates bone marrow; Hb, hemoglobin; ANC, absolute neutrophil count; HI-E, hematological improvement in erythroid series; Tx, transfusion; HI-P, hematological improvement in platelets; Plt, platelets; for other abbreviations, see Table1.
Unique Rush Cancer Institute patient numbers.
Plus sign indicates a continuing response.